1,2-二芥酰-SN-甘油-3-磷酰胆碱 | 51779-95-4

• 物质功能分类: 有机原料 - 有机膦化合物
• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 甘油磷脂
• 中文名称: 1,2-二芥酰-SN-甘油-3-磷酰胆碱
• 中文别名: L-二芥酰卵磷脂；二芥酰磷脂酰胆碱
• 英文名称: 1,2-dierucil-sn-glycero-3-phosphocholine
• 英文别名: DEPC；1,2-dierucoyl-sn-glycero-3-phosphocholine；[(2R)-2,3-bis[[(Z)-docos-13-enoyl]oxy]propyl] 2-(trimethylazaniumyl)ethyl phosphate
• CAS: 51779-95-4；76420-81-0
• 化学式: C₅₂H₁₀₀NO₈P
• 分子量: 898.342
• InChiKey: SDEURMLKLAEUAY-JFSPZUDSSA-N

物化性质

• 熔点：
  211- 214° C
• 沸点：
  480 °C
• 溶解度：
  可溶于氯仿（轻微）、DMSO（轻微、加热、超声处理）、甲醇（轻微）
• 物理描述：
  Solid

计算性质

• 辛醇/水分配系数(LogP)：
  18.1
• 重原子数：
  62
• 可旋转键数：
  50
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.88
• 拓扑面积：
  111
• 氢给体数：
  0
• 氢受体数：
  8

安全信息

• WGK Germany：
  3

文献信息

• FLUORESCENT ANTICANCER PLATINUM DRUGS
  申请人：INVICTUS ONCOLOGY PVT. LTD.

  公开号：US20180312534A1

  公开（公告）日：2018-11-01

  The present disclosure is in relation to the field of nanotechnology and cancer therapeutics. In particular, the present disclosure relates to fluorescent platinum based compounds. The disclosure further relates to synthesis of said fluorescent platinum based compounds, nanoparticles and compositions comprising said fluorescent platinum based compounds/nanoparticles. The disclosure also relates to methods of managing cancer by the fluorescence changes between aforesaid platinum based compounds and corresponding free ligands, nanoparticles and compositions.

  本公开涉及纳米技术和癌症治疗领域。具体而言，本公开涉及荧光铂基化合物。该公开进一步涉及合成所述荧光铂基化合物、纳米颗粒和包含所述荧光铂基化合物/纳米颗粒的组合物。该公开还涉及通过上述铂基化合物与相应的游离配体、纳米颗粒和组合物之间的荧光变化来管理癌症的方法。
• [EN] FUSOGENIC LIPOSOMES, COMPOSITIONS, KITS AND USE THEREOF FOR TREATING CANCER<br/>[FR] LIPOSOMES FUSOGÈNES, COMPOSITIONS, KITS ET LEUR UTILISATION POUR LE TRAITEMENT DU CANCER
  申请人：APA ADVANCED TECH LTD

  公开号：WO2018193451A1

  公开（公告）日：2018-10-25

  A fusogenic liposome comprising a lipid bilayer comprising a plurality of lipid molecules having 14 to 24 carbon atoms, wherein at least one of said lipid molecules is functionalised with a first functional group of a specific binding pair capable of binding to a complementary second functional group of said binding pair; and optionally further comprising an immune system activating agent functionalised with a complementary second functional group of said binding pair bound to said first functional group is provided. Methods of treatment of cancer using the fusogenic liposome are also provided.

  一种融合素脂质体，包括一个脂质双层，其中包括14至24个碳原子的多种脂质分子，其中至少一个脂质分子被功能化为能够结合到特定结合对的亲和性第一功能基团的功能基团；并且可选地进一步包括一个免疫系统激活剂，其被功能化为能够结合到所述结合对的亲和性第二功能基团的互补第二功能基团，结合到所述第一功能基团。还提供了使用这种融合素脂质体治疗癌症的方法。
• Sustained-release liposomal anesthetic compositions
  申请人：Kim Sinil

  公开号：US20060078606A1

  公开（公告）日：2006-04-13

  The invention provides a method for obtaining local anesthetics encapsulated in liposomes, such as multivesicular liposomes, with high encapsulation efficiency and slow release in vivo. When the encapsulated anesthetic is administered as a single intracutaneous dose, the duration of anesthesia and half-life of the drug at the local injection site is increased as compared to injection of unencapsulated anesthetic. The maximum tolerated dose of the encapsulated anesthetic is also markedly increased in the liposomal formulation over injection of unencapsulated anesthetic. These results show that the liposomal formulation of local anesthetic is useful for sustained local infiltration and nerve block anesthesia.

  该发明提供了一种获取包埋在脂质体中（如多囊脂质体）的局部麻醉药物的方法，具有高包埋效率和缓慢释放的特点。当包埋的麻醉药物作为单次皮内注射剂给予时，与未包埋麻醉药物注射相比，局部注射部位的麻醉持续时间和药物的半衰期增加。在脂质体制剂中，包埋的麻醉药物的最大耐受剂量也显著增加，而未包埋麻醉药物的注射则没有这种效果。这些结果表明，局部麻醉药物的脂质体制剂对于持续的局部浸润和神经阻滞麻醉是有用的。
• HYDROPHILIC FLUORINATED MOLECULES FOR LIPOSOMAL 19F MRI PROBES WITH UNIQUE MR SIGNATURES
  申请人：TEXAS CHILDREN'S HOSPITAL

  公开号：US20180154025A1

  公开（公告）日：2018-06-07

  Readily available hydrophilic and small organofluorine moieties were condensed via “click chemistry” to generate nonionic hydrophilic fluorinated molecules with unique 19 F MR signatures. These were used to fabricate stable liposome formulations for imaging various tissue types. This approach was tailored to exploit the broad spectrum of organic 19 F molecular species and to generate probes with distinct 19 F MRI signatures for simultaneous assessment of multiple molecular targets within the same target volume.

  通过“点击化学”将易得的亲水性和小的有机氟基团缩合，生成具有独特的19F MR标记的非离子亲水性氟化分子。这些分子被用于制备稳定的脂质体配方，用于成像各种组织类型。这种方法旨在利用有机19F分子种类的广泛谱，生成具有不同19F MRI标记的探针，以同时评估同一目标体积内多个分子靶标。
• [EN] RELEASABLE CATIONIC LIPIDS FOR NUCLEIC ACIDS DELIVERY SYSTEMS<br/>[FR] LIPIDES CATIONIQUES LIBÉRABLES POUR SYSTÈMES D'ADMINISTRATION D'ACIDES NUCLÉIQUES
  申请人：ENZON PHARMACEUTICALS INC

  公开号：WO2010057155A1

  公开（公告）日：2010-05-20

  The present invention is directed to releasable cationic lipids and nanoparticle compositions for the delivery of nucleic acids and methods of modulating an expression of a target gene using the same. In particular, the invention relates to cationic lipids including an acid labile linker, and nanoparticle compositions containing the same.

  本发明涉及可释放的阳离子脂质和纳米颗粒组合物，用于传递核酸并利用其调节靶基因的表达的方法。具体而言，本发明涉及包含酸敏感连接剂的阳离子脂质和含有该连接剂的纳米颗粒组合物。